<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35147070</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The combination of MnO<sub>2</sub>@Lipo-coated gefitinib and bevacizumab inhibits the development of non-small cell lung cancer.</ArticleTitle>
        <Pagination>
          <StartPage>466</StartPage>
          <EndPage>477</EndPage>
          <MedlinePgn>466-477</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2022.2032872</ELocationID>
        <Abstract>
          <AbstractText>It can be found from a large number of cancer treatments that use of anti-cancer drugs alone often presents low efficacy and high side effects. This study aims to develop a new drug carrier with tumor-specific response, controlled release <i>in vivo</i> and high tumor-suppressive property. Inorganic nano-materials MnO<sub>2</sub> with pH and glutathione (GSH, abundant in cancer cells) responsiveness were used to construct sustained-release functional nano-liposome to be an excellent <i>in vivo</i> pH-sensitive drug delivery system. Some hydrophilic MnO<sub>2</sub>, gefitinib (Geb), and bevacizumab (Beb) were encapsulated in the phospholipid vesicles (liposomes), so as to integrate several anti-tumor drugs (MnO<sub>2</sub>-PDA@Lipo@Geb@Beb) to achieve effective treatment of non-small cell lung cancer (NSCLC). Part of the MnO<sub>2</sub> nanorods on the lipid shell had the properties of pH and GSH responsiveness, which could further enhance anti-cancer efficacy. Cell assay results showed that MnO<sub>2</sub>-PDA@Lipo@Geb@Beb nano-drug had an effective inhibition on A549 cell progression and showed excellent biocompatibility. <i>In vivo</i> results further confirmed that MnO<sub>2</sub>-PDA@Lipo@Geb@Beb nano-drug could effectively inhibit the growth of NSCLC cells. Overall, it can be inferred from the above experimental results that the nanocomposite drug is expected to be widely used in the clinical application of lung cancer.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Jisong</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, School of Medicine, Cancer Center, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, School of Medicine, Cancer Center, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Huihui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, School of Medicine, Cancer Center, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Enguo</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, School of Medicine, Cancer Center, Zhejiang University, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017895">Manganese Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010087">Oxides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>2S9ZZM9Q9V</RegistryNumber>
          <NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S65743JHBS</RegistryNumber>
          <NameOfSubstance UI="D000077156">Gefitinib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>TF219GU161</RegistryNumber>
          <NameOfSubstance UI="C016552">manganese dioxide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068258" MajorTopicYN="N">Bevacizumab</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002626" MajorTopicYN="N">Chemistry, Pharmaceutical</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D065546" MajorTopicYN="N">Drug Liberation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077156" MajorTopicYN="N">Gefitinib</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006863" MajorTopicYN="N">Hydrogen-Ion Concentration</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017895" MajorTopicYN="N">Manganese Compounds</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D043942" MajorTopicYN="N">Nanotubes</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010087" MajorTopicYN="N">Oxides</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013499" MajorTopicYN="N">Surface Properties</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">NSCLC</Keyword>
        <Keyword MajorTopicYN="N">Specific response</Keyword>
        <Keyword MajorTopicYN="N">biocompatibility</Keyword>
        <Keyword MajorTopicYN="N">pH-sensitive</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no potential conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>11</Day>
          <Hour>8</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35147070</ArticleId>
        <ArticleId IdType="pmc">PMC8843201</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2022.2032872</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Alizadeh AA, Aranda V, Bardelli A, et al.  (2015). Toward understanding and exploiting tumor heterogeneity. Nat Med
21:846–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4785013</ArticleId>
            <ArticleId IdType="pubmed">26248267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allen TM, Cullis PR. (2013). Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev
65:36–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23036225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barenholz Y. (2003). Relevancy of drug loading to liposomal formulation therapeutic efficacy. J Liposome Res
13:1–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12725720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen H, Chen Z, Kuang Y, et al.  (2018). Stepwise-acid-active organic/inorganic hybrid drug delivery system for cancer therapy. Colloids Surf B Biointerfaces
167:407–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29704741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen LJ, Yang CX, Yan XP. (2017). Liposome-coated persistent luminescence nanoparticles as luminescence trackable drug carrier for chemotherapy. Anal Chem
89:6936–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28605896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drummond DC, Meyer O, Hong K, et al.  (1999). Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev
51:691–743.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10581328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghosh K, Yue CY, Sk MM, Jena RK. (2017). Development of 3D urchin-shaped coaxial manganese dioxide@polyaniline (MnO2@PANI) composite and self-assembled 3D pillared graphene foam for asymmetric all-solid-state flexible supercapacitor application. ACS Appl Mater Interfaces
9:15350–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28414212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han Y, Li Y, Zhang P, et al.  (2016). Nanostructured lipid carriers as novel drug delivery system for lung cancer gene therapy. Pharm Dev Technol
21:277–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25560648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Q, Chen J, Yan J, et al.  (2020). Tumor microenvironment responsive drug delivery systems. Asian J Pharm Sci
15:416–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7486519</ArticleId>
            <ArticleId IdType="pubmed">32952667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin H, Wan C, Zou Z, et al.  (2018). Tumor ablation and therapeutic immunity induction by an injectable peptide hydrogel. ACS Nano
12:3295–310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29558107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lasic DD, Frederik PM, Stuart MC, et al.  (1992). Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett
312:255–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1426260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li B, Rong G, Xie Y, et al.  (2006). Low-temperature synthesis of alpha-MnO2 hollow urchins and their application in rechargeable Li batteries+. Inorg Chem
45:6404–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16878952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao L, Liu J, Dreaden EC, et al.  (2014). A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin. J Am Chem Soc
136:5896–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4105175</ArticleId>
            <ArticleId IdType="pubmed">24724706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu D, Liu F, Liu Z, et al.  (2011). Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody. Mol Pharm
8:2291–301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21923159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu G, Ma J, Li Y, et al.  (2017). Core-interlayer-shell Fe3O4@mSiO2@lipid-PEG-methotrexate nanoparticle for multimodal imaging and multistage targeted chemo-photodynamic therapy. Int J Pharm
521:19–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28163230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Chen XG, Yang PP, et al.  (2019). Tumor microenvironmental pH and enzyme dual responsive polymer-liposomes for synergistic treatment of cancer immuno-chemotherapy. Biomacromolecules
20:882–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30621390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lohcharoenkal W, Wang L, Chen YC, Rojanasakul Y. (2014). Protein nanoparticles as drug delivery carriers for cancer therapy. Biomed Res Int
2014:180549.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3977416</ArticleId>
            <ArticleId IdType="pubmed">24772414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lusic H, Grinstaff MW. (2013). X-ray-computed tomography contrast agents. Chem Rev
113:1641–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3878741</ArticleId>
            <ArticleId IdType="pubmed">23210836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maeda H, Wu J, Sawa T, et al.  (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release
65:271–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10699287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papahadjopoulos D, Allen TM, Gabizon A, et al.  (1991). Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A
88:11460–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC53155</ArticleId>
            <ArticleId IdType="pubmed">1763060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prasad R, Chauhan DS, Yadav AS, et al.  (2018). A biodegradable fluorescent nanohybrid for photo-driven tumor diagnosis and tumor growth inhibition. Nanoscale
10:19082–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30288516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prasad R, Yadav AS, Gorain M, et al.  (2019). Graphene oxide supported liposomes as red emissive theranostics for phototriggered tissue visualization and tumor regression. ACS Appl Bio Mater
2:3312–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">35030773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qu Q, Zhang P, Wang B, et al.  (2009). Electrochemical performance of MnO2 nanorods in neutral aqueous electrolytes as a cathode for asymmetric supercapacitors. J Phys Chem C
113:14020–7.</Citation>
        </Reference>
        <Reference>
          <Citation>Selvakumar M, Srivastava P, Pawar HS, et al.  (2016). On-demand guided bone regeneration with microbial protection of ornamented SPU scaffold with bismuth-doped single crystalline hydroxyapatite: augmentation and cartilage formation. ACS Appl Mater Interfaces
8:4086–100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26799576</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. (2015). Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release
200:138–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25545217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu M-X, Yan H-J, Gao J, et al.  (2018). Multifunctional supramolecular materials constructed from polypyrrole@UiO-66 nanohybrids and pillararene nanovalves for targeted chemophotothermal therapy. ACS Appl Mater Interfaces
10:34655–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30226739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yanasarn N, Sloat BR, Cui Z. (2011). Negatively charged liposomes show potent adjuvant activity when simply admixed with protein antigens. Mol Pharm
8:1174–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3148289</ArticleId>
            <ArticleId IdType="pubmed">21615153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang G, Xu L, Chao Y, et al.  (2017). Hollow MnO2 as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. Nat Commun
8:902.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5638920</ArticleId>
            <ArticleId IdType="pubmed">29026068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ying M, Zhan C, Wang S, et al.  (2016). Liposome-based systemic glioma-targeted drug delivery enabled by all-d peptides. ACS Appl Mater Interfaces
8:29977–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27797175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zamboni WC. (2005). Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res
11:8230–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16322279</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang F, Chen D, Wang Y, et al.  (2017). Lysosome-dependent necrosis specifically evoked in cancer cells by gold nanorods. Nanomedicine
12:1575–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28478730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang JL, Srivastava RS, Misra RD. (2007). Core-shell magnetite nanoparticles surface encapsulated with smart stimuli-responsive polymer: synthesis, characterization, and LCST of viable drug-targeting delivery system. Langmuir
23:6342–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17461602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang T, Zhou W, Jia Z, et al.  (2018). Polydopamine-assisted functionalization of heparin and vancomycin onto microarc-oxidized 3D printed porous Ti6Al4V for improved hemocompatibility, osteogenic and anti-infection potencies. Sci China Mater
61:579.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Wu L, Jiang C, Yan B. (2015). Reprogramming cellular signaling machinery using surface-modified carbon nanotubes. Chem Res Toxicol
28:296–305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25536342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu S, Chen Z, Wang L, et al.  (2018). A combination of SAHA and quinacrine is effective in inducing cancer cell death in upper gastrointestinal cancers. Clin Cancer Res
24:1905–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29386219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zununi Vahed S, Salehi R, Davaran S, Sharifi S. (2017). Liposome-based drug co-delivery systems in cancer cells. Mater Sci Eng C Mater Biol Appl
71:1327–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27987688</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
